Research amongst veterinary surgeons by Janssen Animal Health, maker of Cavalesse oral and Cavalesse topical, has revealed that owners could be doing more harm than good when it comes to managing sweet itch in their horses.
92% of vets questioned are aware that people follow old wives' tales by administering lotions and potions such as garlic and olive oil to ward off flies during the summer sweet itch season, when garlic actually has the opposite effect of attracting them.
According to Janssen, it is thought that only a quarter of horse owners are aware that it is important to carry out preventative measures before the start of the midge season to help alleviate sweet itch. 14% of people are thought to go to their vet for advice on sweet itch, while 30% seek help from their country store or tack shop, 27% search for information on websites and 26% ask other horse owners for guidance. This is despite the fact that 92% of those questioned believe that sweet itch would clear up quicker if people sought advice from their veterinary surgeon.
Nicki Glen, marketing manager at Janssen Animal Health said: "Sweet itch can be an incredibly difficult and frustrating condition to manage, however horse owners do not tend to seek advice from their vets. It is therefore important to educate horse owners while you are on yard visits with pro-active advice on the condition for the long-term health and welfare of horses."
Cavalesse is a natural food supplement containing a specialised formulation of water-soluble vitamins and minerals, including nicotinamide. Once a month the contents of each sachet are dissolved in water to form an oral solution, which can be administered daily via a special pipette, either by sprinkling over a small handful of feed or adding to a treat such as a sugar lump. Janssen says the supplement helps horses maintain a healthy skin and promotes normal immune function in horses prone to summer allergies.
Cavalesse Topical is a skincare gel that can be used in combination with the Cavalesse solution. The gel can be applied to the skin to help support natural immunity from the outside, whilst the oral solution works in partnership from the inside.
For further information on Cavalesse and Cavalesse Topical please contact your Janssen Animal Health account manager or phone 01494 567555.
Veterinary practices are being encouraged to enter the annual Veterinary Marketing Association's (VMA) awards, which now include a practice-only category.
The annual VMA awards are intended to recognise excellence in all aspects of veterinary and animal health marketing. The Practice Marketing Award, sponsored by Pfizer, is awarded to the companion or production animal practice that demonstrates the most initiative and innovation in the marketing of its products and/or services to end users. This can involve the use of any form of activity, including advertising, websites, direct mail and media relations.
Last year's winner of this award was Kessock Equine Vets from Aberdeen, who travelled down to London to receive their award at a presentation lunch. The 2009 awards presentation ceremony takes place on Friday, 19th March at the Old Brewery in Chiswell Street, London. The meeting also presents a very good opportunity for vets to meet representatives from all the major animal health companies.
Tickets for the event cost £115+VAT for VMA/VMPA members (£150+VAT for non-members). The price includes a three-course meal (prepared by a two-star Michelin chef) with wine, a champagne reception and entertainment by a top comedian.
Further information on the awards is available on the Veterinary Marketing Association's website - http://www.vma.org.uk/. Closing date for entries is 5th February 2010.
Gil Riley of the Pool House Veterinary Hospital in Lichfield, Staffordshire has won the annual Petplan Equine Vet of the Year Award.
The Award was announced at the 21st annual Animal Health Trust (AHT) Equestrian Awards gala dinner held at the Lancaster Hotel in London last Thursday.
Horse owners from all over the UK nominated vets who had gone above and beyond the call of duty. A short list of three finalists was then drawn up and the winner selected by an independent panel consisting of: Peter Webbon AHT Chief Executive and Equine Vet, Alison Bridge Editor-in-Chief of Horse & Rider Magazine, Chris House President of the British Equine Veterinary Association (BEVA) and Jo Whitaker Marketing Development Manager for Petplan.
Peter Webbon of the AHT said "We received a record number of nominations this year and the standards were incredibly high. However, Gil was nominated by over 100 clients and we felt he was truly deserving of this award."
Alison Andrew, Marketing Manager for Petplan said: "This award recognises the amazing hard work and commitment of people within the equine veterinary profession and those who provide outstanding service to horse owners."
Gil joined the Pool House Veterinary Group and Equine clinic practice to expand his equine skills after working in a mainly agricultural practice in Wales and is jointly responsible for the Equine part of the Practice. He has subsequently been awarded the Royal College of Veterinary Surgeons Certificate in Equine Practice and he is particularly interested in lameness and laminitis. He also recently acted as British Team Vet at the International Driving Trials in Germany.
Gil said: "Everyday I feel like I'm pulling the greatest trick in that I get paid for doing what I love. To receive further recognition with this award almost feels greedy. I'm tremendously flattered and indebted to all my clients who nominated me."
In his acceptance speech Gil praised his team for their dedication and support without whom, he said this would not have been possible. Special thanks went to his proud wife Emma on the evening of their fifth wedding anniversary.
The Animal Health Trust Equestrian awards are designed to recognise the outstanding achievements made by horses, riders, owners and trainers throughout the equestrian world. Since the Petplan Charitable Trust was founded in 1994 it has raised over £5million, almost £500,000 of which has been donated to the AHT to fund research and development.
VetCell Bioscience has become the first UK-based stem cell centre to be authorised under the Veterinary Medicines Regulations.
Following a rigorous series of inspections and reports by Good Manufacturing Practice (GMP) Inspectors VetCell, in conjunction with their UK laboratory partner Biobest, were officially authorised as an equine stem cell centre on 1 October 2009.
David Mountford, Chief Operating Officer of VetCell Bioscience said: "To have received formal authorisation so swiftly reflects the high standard of our operation and our ability to lead the field in the increasingly competitive sector of stem cell technology."
Stem cell therapy involves implanting millions of the animal's own stem cells and autologous growth factors directly into the injured tendon or ligament. The service VetCell Bioscience offers is the collection, storage, processing and supply of stem cells suitable for administration back into the donor animal.
According to the company, there is considerable interest from the human sector and studies in human medicine, for the treatment of Achilles tendinopathies, could begin as early as next year.
Petplan, the pet insurance provider has been selected as a Which? Best Buy. The independent consumer guide selected Petplan's 'Covered For Life' policy that covers animals for accidents and illnesses, including reoccurring conditions, such as diabetes and glaucoma, year after year, as long as the policy is renewed annually.
Alison Andrew, Petplan's Marketing Manager said: "The Which? report is crucial to being acknowledged as a worthy pet insurance provider. We feel being selected as a Which? Best Buy reflects how we treat our customers by offering excellent customer service, paying claims quickly, discounts on pet products and regular information about pet care through our magazine PetPeople."
Petplan provides insurance cover for dogs, cats, rabbits and horses and is the largest provider of animal health insurance in the world.
The Disciplinary Committee of the RCVS has approved an application for restoration to the Register from an Oxfordshire veterinary surgeon who had been struck off for false certification.
In November 2007, the Committee decided that Mr John Williams, of the Avonvale Veterinary Practice in Ratley, near Banbury, should have his name removed from the RCVS Register, having found him guilty of disgraceful professional conduct. Mr Williams had admitted signing export health certificates for three horses in October 2006 to state that they had received negative test results for the contagious equine metritis organism, before these results were actually available.
At the time, Mr Williams was working in his capacity as an Official Veterinarian (OV) for DEFRA and he had previously been suspended from his official duties on three separate occasions, on the basis of export certification irregularities. It was accepted that Mr Williams had not been dishonest, but his approach to certification was described by the Disciplinary Committee as "either irresponsible or cavalier or both".
In December 2007, Mr Williams appealed against this decision to the Privy Council but this was dismissed at a Hearing the following June. He was then removed from the Register in July 2008.
When the Committee met on Monday to consider Mr Williams' application, they heard oral and written supporting evidence from veterinary surgeons and equine clients, and oral evidence from Mr Williams himself. The Committee was satisfied that Mr Williams accepted its previous findings and fully understood their seriousness. He described his removal from the Register as a "salutary experience" which had been highly significant for him and his family, both financially and emotionally.
The Committee stated: "Although the decision of the Committee to remove [Mr Williams] from the Register sent a clear message to the profession of the importance of certification, it should be emphasised that his removal was the consequence of his actions in signing certificates which he could not verify. This followed three previous occasions on which he had similarly signed certificates when he should not have done so."
However, the Committee was satisfied that Mr Williams would not in future sign certificates when he should not do so, even under severe client pressure. It was impressed with the continuing professional development he had undertaken whilst off the Register and noted that no questions had been raised over his conduct during this time.
It concluded that Mr Williams fully understood the importance of accurate certification and that restoring his name to the Register therefore posed no risk to animal welfare. Neither the public nor the profession would benefit from Mr Williams staying off the Register for a further period.
Alison Bruce, Disciplinary Committee Chairman, said: "We would like to make it clear that we always find it distressing to remove clinically competent veterinary surgeons from the Register because of an irresponsible and cavalier attitude towards certification. This would not be necessary if veterinary surgeons were to follow the Twelve Principles of Certification annexed to the RCVS Guide to Professional Conduct."
The Committee then approved Mr Williams' application and directed that his name should be restored to the Register.
An international group of scientists has published new results that herald a breakthrough in finding a vaccine against the most commonly diagnosed infectious disease of horses, strangles.
UK experts from the Animal Health Trust collaborated with scientists from the Swedish University of Agricultural Sciences (SLU), the Karonlinska Institutet Medical University and Intervacc AB, on the project - the results of which could benefit humans as well as animals.
Professor Andrew Waller, Head of Bacteriology at the AHT, said: "We have been working towards developing a vaccine for 7 years, and finally it seems as if all the hard work is paying off. We've already developed better ways of diagnosing exposure to the infection, and now, with the success of creating a safe and effective vaccine, it looks as if we're finally bringing together the tools necessary to eradicate this terrible disease."
The vaccine consists of seven different Streptococcus proteins and results from early tests published in PLoS Pathogens have been incredibly positive showing a high level of protection and no side effects. It is hoped that the strangles vaccine could be commercially available in the near future.
Streptococcus equi, the bacterium that causes strangles, shares 80 per cent identity with Streptococcus pyogenes - the leading cause of bacterial pharyngitis, tonsillitis and rheumatic fever in humans, which kills thousands of people each year. Scientists hope that the knowledge gained through developing the strangles vaccine will also help in developing vaccines to combat these human conditions.
Research leader, Professor Bengt Guss of SLU, said: "This is a most exciting project, where research is generating new applications and knowledge that can be used to develop vaccines against these important bacteria. This is particularly important considering the increased number of infectious diseases caused by antibiotic-resistant bacteria."
The vaccine development work was only made possible thanks to information from the Streptococcus equi genome sequencing project funded by The Horse Trust.
The Horse Trust's Chief Executive Brigadier Paul Jepson, said: "We are absolutely delighted that by pulling apart the genome of this plague of the horse world scientists have generated a truly safe and effective strangles vaccine. That this work could also benefit other animal and human health is beyond our wildest hopes."
Full text of the research findings can be found in PLoS Pathogens online at http://www.plospathogens.org/article/info%3Adoi%2F10.1371%2Fjournal.ppat.1000584
A new equine parasite supplement to the online peer-reviewed publication Parasites and Vectors has been published by Fort Dodge.
Entitled "Equine parasites: diagnosis and control - a current perspective," it contains papers on a range of topics including a major European resistance study into key anthelmintic molecules. It is authored by equine parasitology experts and opinion leaders from around the world and was first published in September 2009. It is freely available at http://www.parasitesandvectors.com/
The National Office of Animal Health (NOAH) has launched a new 'Use Medicines Responsibly' campaign.
The main thrust of the campaign is an initiative by NOAH to encourage pharmaceutical companies to add: 'Use Medicines Responsibly' as a strapline to their own advertising campaigns, with a link to the NOAH information resource for prescribers and users of animal medicines: www.noah.co.uk/responsible.
Speaking at the NOAH annual members' conference in Northampton, NOAH chief executive Phil Sketchley said: "NOAH believes responsible promotion of animal medicines to be an important link in the chain towards responsible use. Companies' promotional material can educate prescribers and users of animal medicines to the benefit of their animals' health and welfare.
"We believe this new advice resource, with the reminder on advertisements, will help."
VetHelpDirect.com, a website which helps pet owners decide how urgently their pet needs veterinary attention, has been relaunched with new content for donkey, reptile and bird owners.
Founded by VetSurgeon member Susie Samuel MRCVS in 2006, the site allows pet owners to look up the symptoms their animal is displaying. When the owner answers a series of simple, step-by-step questions, the site then generates a priority rating from "Self care - treatment at home" to "Urgent - you need to contact your vet immediately", coupled with specific first aid advice. It's a sort of home triage system.
VetHelpDirect was designed by vets and all of the content is by vets. The site covers dogs, cats, rabbits, horses and now donkeys, reptiles and birds. I see that the world-renowned avian vet (and all-round good bloke) Neil Forbes FRCVS and his team at Great Western Referrals, together with Dr Karen Rickards, head vet at the Donkey Sanctuary have helped create the new areas of the website, so the information it contains will certainly be of the highest standard.
In fact, the whole site is impressively well-designed and simple to use, an opinion obviously echoed by the readers of WebUser magazine, who gave it 5/5 stars last May, beating Jamie Oliver's website.
Cleverly, the triage system on VetHelpDirect ties in with a directory of veterinary practices, so if immediate care is the answer and the owner doesn't have a vet already, help is at hand. Veterinary practices can pay to have an enhanced listing in the directory.
For a fee, VetHelpDirect can also embed the triage system into your own practice website. That seems like a good way of adding additonal, interesting and interactive content to a website. The interesting question is how much money it will save the practice by eliminating unecessary calls from pet owners who don't really need to talk to a vet.
Equally, though, the site may have an important role to play in telling owners when they SHOULD get to the vet quickly. A recent success story was that of 'Bucket', a 5 year old cat from Nottingham. Bucket was fortunate to live after his owner Sarah Rennoldson logged on to Vet Help Direct.com after he displayed odd behaviour. Acting on the advice displayed on the site her owner immediately contacted her local vet Jaqui Gilmour MRCVS at Bill Bowlers Vets. Bucket was diagnosed with a blocked bladder, which was quickly operated on. Jaqui said: ' If Sarah hadn't brought Bucket in so quickly, he could have gone into renal failure and could have developed metabolic disturbances. He would have been really, really sore, and left untreated a blocked bladder can cause death.'
For more information, 'Start a Conversation' with Susie Samuel MRCVS
Equistro® has produced a dust-free pelleted presentation of Secreta Pro, following requests from clients. Secreta Pro-Max® was launched to vets at BEVA Congress.
Secreta Pro is a respiratory supplement used to support the bronchial system and natural defences on a long term basis.
For more information on Secreta Pro-Max® and all Equistro products, please visit http://www.equistro.co.uk/, or contact your Vetoquinol representative.
Boehringer Ingelheim Vetmedica has launched a unique and natural muscle building supplement for horses, Equitop Myoplast Power Pearls, containing 18 key amino acids.
The company says maintaining muscular condition in performance and sports horses can be challenging, especially when work load is increased or during periods of convalescence, as feeding high levels of concentrates can often lead to horses becoming 'fizzy' and bulking up on fats and oils.
Scientifically designed to support lean muscle growth, not bulk, Equitop Myoplast Power Pearls is great for optimising performance in horses in intensive training and competition, as well as bringing on young, breeding and injured animals, and for older horses which lose condition easily.
The product is endorsed by top British show jumper, Ellen Whitaker and veterinary surgeon and dressage rider, Christel Robbins BVSc MRCVS.
Craig Beck from Boehringer Ingelheim Vetmedica said: "Equitop Myoplast Power Pearls is already one of the most popular equine supplements sold in Germany and is used by top riders in all disciplines to help ensure their horses reach their full athletic potential. We are certain that with the support of riders such as Ellen Whitaker, Equitop Myoplast Power Pearls will prove just as popular in the UK."
Equitop Myoplast Power Pearls is available in a 1.5kg tub (RRP £65) and can be fed separately or mixed with feed. Horses weighing less than 500kg should be fed one scoop (25g) per day, while larger horses should receive two scoops (50g). Boehringer Ingelheim Vetmedica recommends that Equitop Myoplast Power Pearls is fed for at least a month as results are normally visible within 3-4 weeks.
Boehringer Ingelheim Vetmedica is committed to supporting veterinary practices and Equitop Myoplast Power Pearls will be distributed exclusively by veterinary wholesalers. An extensive advertising campaign in professional equine publications will help raise awareness of Equitop Myoplast Power Pearls and, for a limited period, horse owners and equine professionals can download a voucher from http://www.equitop-myoplast.co.uk/ offering a £15 rebate against their first purchase. Veterinary practices can redeem these vouchers by returning them to Boehringer Ingelheim Vetmedica via a freepost address.
For further information on Equitop Myoplast Power Pearls, please contact your local Boehringer Ingelheim Vetmedica representative, visit www.equitop-myoplast.co.uk or call 01344 746959.
Dechra Veterinary Products, manufacturer and distributor of Equipalazone®, has launched a new website with up-to-date advice and guidance on the subject of equine pain management for horse owners: http://www.equinepainmatters.com/
Dechra says the website offers owners a place to go for information about pain in their horse including causes, diagnosis and the tools and techniques that their vet may use to treat pain. Owners will also be able to download anatomy charts and information leaflets on topics such as pain management, lameness, anaesthesia, sedation, euthanasia, the importance of microchipping and wound management.
Larry King, equine product manager at Dechra said: "This website is great for horse owners as they now have one place to go for information about equine pain matters. It will help them gain a better understanding of managing pain in their horses and the critical role that their vet plays in this area. Veterinary practices can also refer owners to it to support their consultation. This is the first website to put all this information together, so we are sure it will be popular.
"Cards with the new website address are available for practices to hand out to clients. "The website allows clients to browse the site in the comfort of their own home and is also ideal for practices with limited storage space for client information materials."
Dechra also encourages practices that have their own websites to link directly to www.equinepainmatters.com. Practices can order hand-out cards by contacting Dechra on 01743 441632 or email marketing@dechra.com.
CEVA Animal Health has produced a leaflet to help horse owners understand the diagnosis and treatment of navicular disease.
Navicular disease can be difficult to diagnose and management of the condition can be a challenge for both vets and horse owners. The new leaflet helps owners get to grips with all aspects of the disease from the clinical signs to the procedures used to obtain a formal diagnosis. It then covers the various treatment options available including corrective farriery, analgesia, bisphosphonates and surgery. Diagrams and photographs help to ensure that the information is clear, concise and easy to follow.
The leaflet is available to equine vet practices as a useful information source for clients. Please order your free copies from your CEVA sales representative.
The AHT has secured an award of £580,000 from the Wellcome Trust to fund the development of a new diagnostic test for Strangles which takes only 30 minutes.
It's been achieved in part by 'Breaking the Strangles Hold' - a two-year fundraising campaign run by the Animal Health Trust (AHT) and The British Horse Society (BHS),
Money donated from the general public, along with funding from The Horse Trust, has already allowed scientists at the AHT to develop a diagnostic blood test which gives results in 24 hours. The blood test was launched in February 2008 and since then more than 6,700 samples have been tested.
HRH The Princess Royal, who launched the 'Breaking the Strangles Hold' campaign, said: "As an owner who has seen my own horse's affected by this terrible disease, it's wonderful to see such progress being made in a relatively short time.
"The screening test enables owners to know within 24 hours if any of their horses have been exposed to this bacterium. Previously available tests would have taken three to four days. The test is making a real difference in welfare and economic terms for all those involved in the equine industry. It truly is groundbreaking."
The success of this diagnostic work, along with other AHT research, has attracted further funding for the project from the Wellcome Trust in the form of a £580,000 Translation Award.
Professor Andrew Waller, Head of Bacteriology at the AHT, said: "The main problem with Strangles is the time taken to diagnose it. The current blood test is a big step forward, but the culture and DNA tests, which are often used in the initial stages of an outbreak can take a couple of days to get results."
The Translation Award means the AHT can reduce the time taken to perform its DNA diagnostic test and ultimately produce a point-of-care test that vets can use on site to get a diagnosis in 30 minutes. Earlier diagnosis will allow owners to isolate horses sooner and minimise the spread of infection. It will further reduce welfare problems for horses and the cost to their owners.
The AHT and Atlas Genetics will design and validate the point-of-care diagnostic test over the next two years. It is hoped that the test could be mass produced and widely available by 2012.
Professor Waller added: "This technology will be fantastic. It will be hugely beneficial for other diseases too, of both veterinary and clinical importance. Without the money raised through the 'Breaking the Strangles Hold' campaign, we wouldn't have made as much progress. On behalf of horses and horse owners worldwide, I'd like to thank everyone who has donated."
The 'Breaking the Strangles Hold' campaign reached its fundraising target of £250,000 in just two years, demonstrating how important to horse owners it is to get to grips with this terrible disease.
For more information, see: http://www.strangles.org
If you're attending BEVA this September you can win a place on the CEVA-sponsored Equine Ski-PD break in January 2010, combining a couple of days of first class Continued Professional Development (CPD) with some excellent skiing in the Italian Alps.
The course runs from 13-17 January 2009 and the CPD will be spread over five sessions, equating to two-and-a-half days. Equine vets Jane Boswell, Henry Tremaine, Professor Bruce McGorum, Professor Peter Clegg and Dr Tim Brazil will cover the topics of tendonitis, wound management, ophthalmology, internal medicine and joint disease.
Skiing will be at Courmayeur, a traditional Alpine village on the Italian side of Mont Blanc, where all levels of ability, from beginners to experienced off-piste skiers, can be catered for.
To win your place, which includes flights and four nights b&b accommodation, simply visit the CEVA stand at BEVA and answer a questionnaire on Tildren®, CEVA's bisphosphonate-based treatment for equine bone disease, based on information provided via a short film loop that will be running on the stand.
For further information on equine Ski-PD contact the organisers: ben.mayes@equinevetpractice.co.uk or henry.tremaine@bristol.ac.uk
EQVALAN® manufacturer Merial Animal Health is extending its free egg worm count promotion, allowing practices to re-run the offer this autumn.
During September and October Merial is giving away 20 free faecal egg count tests with each order of 20 tubes of EQVALAN® DUO (ivermectin + praziquantel). In addition, for every 20 tubes ordered, stockists will get a further 4 tubes of EQVALAN® DUO free.
EQVALAN's product manager Claire Edmunds said: "During the spring campaign, over 1000 horse owners took part in the worm egg count promotion, many of whom we believe had never used testing kits before.
"The tests highlight which horses need treatment and which do not, allowing practices to advise specifically on the necessary treatment*.
For those practices with their own testing facilities, Merial is also offering promotional support to help encourage increased uptake and client buy-in. "The autumn campaign will provide participating practices with another opportunity to add value whilst encouraging loyalty from clients.
Claire added: "Promoting a targeted approach to responsible worming means that only those horses which need treatment are wormed with an appropriate wormer selected for the worms identified from the test."
For further information please contact your local territory manager or call the Merial Customer Support Centre on 0845 601 4236.
Merial has launched a 'Vaccination Back on Track' promotion via vet practices that administer Merial vaccines.
Under the scheme, owners of all horses over 12 months of age that have not yet been vaccinated against equine influenza or are overdue a booster obtain a primary vaccination course at an attractive discounted rate. A tetanus component is also available if required.
Dr Emma Batson from Merial said: "With continuing cases of equine flu recorded in the UK, and a global increase in the number of serious outbreaks, it has never been more important to ensure that horses are protected against this underestimated threat.
"It's often not fully understood that equine flu can be transferred indirectly via inanimate objects such as horse boxes, fencing or human clothing. With just 37% of horses in the UK estimated to be vaccinated, this leaves a significant naive and vulnerable population at risk".
Merial says there is no limit on the number of horses that can be vaccinated, making it a particularly attractive offer for those with more than one horse or yard(s).
Participating practices have the option to run the scheme in any month between now and December 2009. For information, contact your Merial Territory Manager.
New research, conducted by the WALTHAM-initiated Laminitis Consortium, has raised questions over the assumption that soaking hay will make it safe to feed to laminitis-prone horses and ponies1.
The Laminitis Consortium comprises world-leading equine veterinary, nutrition and research experts interested in collaborating on the important topic of laminitis. It includes the authors of this work: Dr Pat Harris of the WALTHAM® Equine Studies Group, Clare Barfoot of Mars Horsecare UK Ltd and Dr Annette Longland of Equine Livestock and Nutrition Services (ELNS).
Over-consumption of water-soluble carbohydrates (WSC) has been associated with the onset of laminitis. It has been recommended that hay with a non-structural carbohydrate (WSC and starch) content of less than 10% should be fed to obese animals as well as those at risk of laminitis2 and that hay should be soaked in water before being fed in order to reduce the WSC3,4,5. The study, which was completed earlier this year, examined the loss of water-soluble carbohydrates from nine different hays submerged in water for up to 16 hours. It was presented to the biannual Equine Science Symposium in America in May 2009.
Previous studies have shown that the prolonged soaking of chopped hay in large volumes of water can result in the leaching of nutrients, including soluble carbohydrates. However, because common practice in the UK tends to involve long-stemmed hay, soaked in relatively small volumes of water over varying timescales, the Laminitis Consortium's study aimed to replicate such a practice6.
The nine different hay samples were analysed for WSC and then soaked in cold water. The soaked samples were subsequently analysed at four intervals of 20 minutes, 40 minutes, three hours and 16 hours.
Clare Barfoot said: "The results showed a highly variable leaching of WSC and substantially less leaching than reported previously for chopped hay soaked for 30 minutes.3
"Very few samples reached below 10% WSC, despite prolonged soaking. The concern is that this strongly suggests that soaking may not be sufficient to render some hays safe to feed to horses and ponies prone to laminitis.
"Our current advice is that ideally you should analyse your hay before feeding it to an animal at high risk of laminitis and choose hay with the lowest WSC content you can find. Soaking hay provides an additional safeguard but should not be relied upon."
The study also highlights that if hay is soaked for extended periods, it may not meet the nutritional requirements of the animal because substantial amounts of other nutrients, protein, vitamins and minerals will also be lost 5. In such cases it is even more important that the horse or pony should receive a balanced supplementary feed.
The Laminitis Consortium is continuing its work in this area and hopes to be able to identify practices that will be of greater benefit to the horse owner faced with hay of unknown WSC content.
1Longland AC Barfoot C & Harris PA (2009) The loss of water- soluble carbohydrate and soluble protein from nine different hays soaked in water for up to 16 hours. J. Equine Vet Science 29 (5 ) p 383 - 384, 2 Frank N Equine Metabolic Syndrome J Equine Vet Sci 29 (5) p 259 - 267, 3Cottrell, E., Watts, K., Duarte, S. and Ralston, S. (2005). Equine Science Symposium, 2005, 4Kenny, D. (2007). Proceedings of the British Society of Animal Science. 5Warr EM, Petch JL. Equine Vet Educ 1993;5:169-171, 6Longland, A.C. (2009) In preparation.
Petplan Equine is now seeking nominations for the Equine Vet of the Year Award 2009, an award to recognise vets that go above and beyond with their care of horses and their owners.
Andrew Dobson of The Barn Equine and Large Animal Practice in Great Wakering, Essex, is the current 2008 Equine of the Year. He was nominated by a number of his grateful clients and their glowing testimonials impressed the judges enough to give him the edge over his closest rivals for the title.
The 37 year old qualified in 1999 and for the last four and a half years has run his own practice. His involvement with horses evolved from a desire to work with large animals and the outdoor life it would bring.
Andrew said: "I was absolutely stunned. I'm so honoured and amazed to have received the Petplan Equine Vet of the Year award. I really enjoy what I do and would like thank all my clients, Petplan Equine and The Animal Health Trust for their support."
If you feel you know a vet that displays equine clinical excellence and fantastic customer care you can nominate online by visiting www.petplanequine.co.uk/events Nominations close 3rd October 2009. An independent panel will judge the nominations and the winning vet will be announced at the Animal Health Trust UK Equestrian Awards in London, in November 2009.
Intervet/Schering-Plough has launched Vectin chewable tablets, an ivermectin wormer for horses which is administered as a treat straight from the hand rather than in the traditional paste or granule formulation.
According to the company, syringe handling, horse acceptance and the tendency to spit out some or all of the paste are common problems reported by owners when worming their horses, and more than 55% admit that these issues can result in a mixture of emotions, including frustration, anxiety and upset.
Field studies with Vectin showed more than 70% spontaneous acceptance by horses and the simple calculation of one tablet for every 110kg of a horse or foal's bodyweight helps to reduce wastage as unused tablets can be stored away for future use.
Pharmacokinetics studies have demonstrated improved bioavailability (AUC) and maximal concentration (Cmax) when compared with an equivalent competitor ivermectin paste formulation. Trials have also shown that a more consistent blood concentration of ivermectin when given as a chew which could potentially limit the chance of inducing resistance.
Intervet/Schering Plough says that used as part of a strategic worming plan, Vectin chewable tablets control potentially a wide range of endoparasites including small and large strongyles, stomach worms, cutaneous worms and stomach bots.
Vectin chewable tablets are available as a seven-tablet blister pack, perfect for treating a horse or a couple of ponies. For yards, a tub of 60 tablets is available, containing enough to dispense product for worming approximately 12 horses.
Vectin chewable tablets are recommended for use alongside Pyratape P and Panacur in Intervet/Schering-Plough Animal Health's Active3 worming plan, a strategic three-year approach to rotating wormers in order to minimize the risk of resistance developing. Visit http://www.intervet.co.uk/ for a copy of the three-year plan.
The Disciplinary Committee (DC) of the Royal College of Veterinary Surgeons last week issued a reprimand to a veterinary surgeon for reckless certification of an equine passport, having found her to have been "wholly indifferent" as to whether the horse had been vaccinated properly against equine influenza.
Eleri Wyn Jones graduated from the University of Liverpool and qualified as a veterinary surgeon in 2006, before joining The Veterinary Practice on Bala Road in Dolgellau, Gwynedd, where she was also an authorised Local Veterinary Inspector (LVI). The principal of that practice is Iwan Parry, who himself was the subject of a DC hearing involving false certification earlier this year, for which he received a one-month suspension from the Register.
The Committee heard how, in late 2007, as Ms Jones was leaving the practice to begin her rounds, she was asked by a non-veterinary colleague to certify in a horse passport that two vaccinations for equine influenza had been administered. The horse in question was being liveried by a regular client of the practice, to whom the practice regularly dispensed veterinary vaccines (although Ms Jones was unaware of this), but had been recently purchased by someone who was not a registered client.
In evidence, Ms Jones admitted the certification process took her only 30 seconds and that she did not obtain any further information about the certification, either from clinical or non-clinical colleagues; nor did she check any other documentation before signing the passport, but assumed the vaccinations had been administered by a veterinary colleague. The Committee had to decide whether Ms Jones had acted recklessly, and to do so, Ms Jones' Counsel suggested the Committee would need to be satisfied that she "did not care less" whether or not the vaccinations had been given by a veterinary surgeon before signing the passport.
In reaching its decision, the Committee took into account the fact Ms Jones, on her own evidence, was generally familiar with RCVS guidance on certification and, as an authorised Local Veterinary Inspector, had certification training. It stated: "Whilst we recognise that Ms Jones received little or no mentoring from Mr Parry, we are satisfied that she would have been aware of the importance of veterinary certification. She was also aware that Mr Parry had been suspended as an LVI, due to certification issues, which had affected her own authorisation."
In view of these facts, and that Ms Jones made no attempt to obtain verification from any other source despite knowing she had not performed the vaccinations herself, the Committee decided that Ms Jones had been "wholly indifferent" to proper vaccination procedures and was therefore guilty of disgraceful professional conduct for reckless certification.
In reaching its decision on sanction, the Committee wished to remind members that cases involving improper certification would ordinarily result in suspension or removal from the Register. "We strongly disapprove of the circumstances in which Ms Jones certified this horse.
Clients, and external bodies, are entitled to rely upon the integrity of the veterinary surgeon in not certifying that horses have been vaccinated unless they have carried out the vaccinations themselves or have obtained full and proper evidence that vaccination has been carried out by another veterinary surgeon," it said.
In mitigation, however, the Committee took into account Ms Jones' age and inexperience, her previously good record, her good character and the significant number of supporting references from colleagues and clients alike. It was also mindful that any sanction's main purpose was to protect animal welfare and maintain public confidence in the profession, rather than to punish.
Nigel Swayne, chairing the Committee, concluded: "This is not a case where undertakings for training or monitoring are required. This isolated incident was a fateful misjudgement on a single occasion. We consider that the sanction most proportionate to the nature and extent of the charge, the public interest and the interests of Ms Jones is a reprimand."
Fort Dodge Animal Health has announced that its Duvaxyn WNV vaccine against West Nile Virus (WNV) is now available in the UK, following its licensing through the European Medicines Agency (EMEA).
Duvaxyn WNV is the first vaccine available in Europe to protect horses against this emerging disease threat. 288 horses and two people in Italy were found to be infected with WNV during the outbreak that hit northern Italy in late 2008 where it is now considered endemic. The disease is endemic in all areas of North America where it has claimed the lives of both horses and humans.
West Nile Virus is caused by a highly contagious flavivirus, which is transmitted by mosquitoes, primarily of the Culex species. The natural hosts of West Nile virus are birds, with migratory birds from Africa carrying the disease. Mosquitoes become infected after taking a blood meal from infected birds and then may transmit the disease to horses and even humans. While horses are 'dead end hosts,' the consequences can be severe as the virus causes encephalitis or meningitis. Mortality rates among horses which develop neurological signs are high and there is no palliative cure for the disease. Treatment is limited to symptomatic relief which can be long and expensive.
Sabrina Jordan, UK Business Manager for Equine Vaccines at Fort Dodge said: "WNV is an increasing threat to the equestrian sector in the UK and is a particular challenge for owners who transport their horses around the world.
"The fact that a vaccine is now available will undoubtedly offer peace of mind to the equestrian community. They can be reassured that horses in the UK can now be vaccinated against WNV with a vaccine that has already been shown to be highly effective in protecting horses in America.
"With any vaccine, a record that a horse has been vaccinated with Duvaxyn WNV should be recorded in its horse passport. By presenting this vaccine in pre-filled syringes with Infovax-ID labels, we've aimed to make both the administration and record keeping of Duvaxyn WNV as convenient as possible.
"To build understanding of this potentially fatal disease threat, we are continuing to work with governments and authorities at a national and European level, as well as working in partnership with the UK's veterinary community to ensure that owners are fully informed about the risk WNV poses and of the benefits of vaccination."
A European study undertaken in horses to evaluate the efficacy of the key anthelmintic molecules fenbendazole, pyrantel, ivermectin and moxidectin in treating equine cyathostomins, has confirmed that resistance is developing against all the molecules with the exception of moxidectin.
Resistance to fenbendazole was highlighted as a particular issue with 80% of the yards tested in the UK and Germany showing resistance. Resistance to pyrantel also proved to be increasingly prevalent while cases of ivermectin resistance were emerging.
The Fort Dodge-sponsored study, the largest of its kind so far undertaken, took place during 2008 and was led by scientific teams from veterinary faculties in Italy and Germany. It was based on Faecal Egg Count Reduction Tests (FECRTs) of 1,704 horses at 102 yards in Italy, Germany and the UK. The calculation of FECR data was performed employing bootstrap analysis of group arithmetic means.
The study concluded that:
According to Dr Donato Traversa from the University of Teramo, Italy, who headed up the field work, the results confirm that single and even multiple drug resistance in equine cyathostomins is an increasing challenge in all three countries with resistance to fenbendazole and pyrantel a particular concern.
He said: "Our research highlights the necessity for vets, owners and managers to use those anthelmintic molecules that remain most effective in a manner which preserves their efficacy for as long as possible."
Professor Georg von Samson Himmelstjerna from Hannover University of Veterinary Medicine, which participated in the research, added: "Given the strong impact that resistant cyathostomins are likely to have on horse welfare, future parasite control plans should be based on integrated measures, involving both the correct use of anthelmintics, such as administering the correct dosing according to the animals weight, and only using products in the species for which it is licensed, as well as other approaches such as adequate pasture hygiene, low stocking rates and mixed grazing with other animals.
"We call on all concerned with equine health and welfare to take an active role in planning and monitoring effective worm control programs."
Fort Dodge has announced that a challenge study has demonstrated the ability of Duvaxyn® IE-T Plus equine influenza vaccine to cross protect against A/equi-2/Sydney/07 (H3N8) two weeks after a two dose primary course. This strain was responsible for the financially devastating equine influenza outbreak in Australia in August 2007.
Duvaxyn IE-T Plus is an inactivated whole virus equine influenza vaccine, adjuvanted with an aqueous-based adjuvant. According to Fort Dodge, experts at a recent WHO meeting on human vaccines expressed the view that whole virus vaccines have the potential to induce a stronger and more broadly based response to circulating influenza strains than those contained in sub-unit vaccines because of the presence of the full set of virus proteins in the vaccine*.
The study, conducted by the Animal Health Trust, involved two groups of EIV seronegative horses. The first group, consisting of seven vaccinates, were given two dose of Duvaxyn IE-T Plus, 28 days apart, and challenged with A/equi-2/Sydney/07 (H3N8) virus strain 14 days after the second vaccination. The second group of unvaccinated horses was challenged at the same time. Duvaxyn IE-T Plus caused a statistically significant reduction in both clinical signs of the disease and in viral shedding.
Helen Barnes, EMEA Equine Business Manager for Fort Dodge, said: "The results of this challenge study provide reassurance for owners that horses vaccinated with Duvaxyn will be protected against circulating strains of equine influenza, including the Sydney strain which proved so damaging.
"As the benefits offered by whole virus technology are increasingly recognised, the popularity of vaccines based on this technology is re-emerging, particularly to combat a potential pandemic.
"The entire Duvaxyn range of equine vaccines, including the recently licensed Duvaxyn WNV for West Nile Virus, are based on the whole virus approach as we believe it offers a broad and consistent level of protection."